MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Начало・Списък с акции・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Затворен

3.95 -1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.87

Максимум

3.95

Ключови измерители
By Trading Economics
Приходи	466K -27M
Продажби	2M 15M
Марж на печалбата	-178.834
Служители	141
EBITDA	-2M -29M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+270.45% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.1M 231M
Предишно отваряне	4.95
Предишно затваряне	3.95

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

3.17 / 3.4644 Подкрепа & съпротива

Voyager Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.04.2026 г., 04:27 ч. UTC

Значими събития в новините

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

5.04.2026 г., 23:55 ч. UTC

Пазарно говорене

Gold Falls Amid Dollar Strength, Inflation Worries -- Market Talk

5.04.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline on Concerns About Energy Costs -- Market Talk

5.04.2026 г., 23:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

5.04.2026 г., 23:42 ч. UTC

Пазарно говорене

China's Consumer Inflation Likely Eased in March -- Market Talk

5.04.2026 г., 23:38 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Rise Amid Increased Supply Disruption Concerns -- Market Talk

5.04.2026 г., 12:57 ч. UTC

Значими събития в новините

Some Italian Airports Report Jet-Fuel Shortages -- WSJ

3.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2026 г., 18:30 ч. UTC

Значими събития в новините

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3.04.2026 г., 18:14 ч. UTC

Пазарно говорене

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3.04.2026 г., 17:50 ч. UTC

Пазарно говорене

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3.04.2026 г., 17:44 ч. UTC

Придобивния, сливания и поглъщания

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3.04.2026 г., 16:50 ч. UTC

Значими събития в новините

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2026 г., 16:12 ч. UTC

Печалби

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3.04.2026 г., 15:56 ч. UTC

Пазарно говорене

Значими събития в новините

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3.04.2026 г., 15:56 ч. UTC

Пазарно говорене

Значими събития в новините

Global Equities Roundup: Market Talk

3.04.2026 г., 15:56 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

3.04.2026 г., 15:20 ч. UTC

Значими събития в новините

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3.04.2026 г., 15:08 ч. UTC

Придобивния, сливания и поглъщания

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3.04.2026 г., 14:11 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3.04.2026 г., 12:56 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2026 г., 08:01 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.04.2026 г., 08:01 ч. UTC

Пазарно говорене

Meituan's Profitability Likely to Improve This Year -- Market Talk

3.04.2026 г., 07:45 ч. UTC

Пазарно говорене

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3.04.2026 г., 06:17 ч. UTC

Пазарно говорене

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3.04.2026 г., 06:17 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.04.2026 г., 04:33 ч. UTC

Пазарно говорене

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3.04.2026 г., 04:33 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Voyager Therapeutics Inc Прогноза

Ценова цел

By TipRanks

270.45% нагоре

12-месечна прогноза

Среден 14.67 USD 270.45%

Висок 25 USD

Нисък 8 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Voyager Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Voyager Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

3.17 / 3.4644Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.